Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011 (2011), Article ID 804041, 10 pages
http://dx.doi.org/10.4061/2011/804041
Review Article

Critical Aspects of Clinical Trial Design for Novel Cell and Gene Therapies

Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK

Received 15 September 2011; Accepted 13 October 2011

Academic Editor: Yoshikazu Ugawa

Copyright © 2011 Zinovia Kefalopoulou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Quinn, “Diagnosis and treatment of Parkinson's disease,” British Medical Journal, vol. 310, no. 6995, pp. 575–579, 1995. View at Google Scholar · View at Scopus
  2. E. Bezard, J. M. Brotchie, and C. E. Gross, “Pathophysiology of levodopa-induced dyskinesia: potential for new therapies,” Nature Reviews Neuroscience, vol. 2, no. 8, pp. 577–588, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. E. Lang and J. A. Obeso, “Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough,” Lancet Neurology, vol. 3, no. 5, pp. 309–316, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. P. J. Garcia Ruiz et al., “Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study,” Movement Disorders, vol. 23, no. 8, pp. 1130–1136, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. Nyholm, A. I. M. Nilsson Remahl, N. Dizdar et al., “Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease,” Neurology, vol. 64, no. 2, pp. 216–223, 2005. View at Google Scholar · View at Scopus
  6. P. Krack, A. Batir, N. van Blercom et al., “Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced parkinson's disease,” New England Journal of Medicine, vol. 349, no. 20, pp. 1925–1934, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. P. D. Charles, C. E. Gill, T. L. Davis, P. E. Konrad, and A. L. Benabid, “Is deep brain stimulation neuroprotective if applied early in the course of PD?” Nature Clinical Practice Neurology, vol. 4, no. 8, pp. 424–426, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Lindvall, P. Brundin, H. Widner et al., “Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease,” Science, vol. 247, no. 4942, pp. 574–577, 1990. View at Google Scholar · View at Scopus
  10. C. R. Freed, R. E. Breeze, N. L. Rosenberg et al., “Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease,” New England Journal of Medicine, vol. 327, no. 22, pp. 1549–1555, 1992. View at Google Scholar · View at Scopus
  11. O. Lindvall, G. Sawle, H. Widner et al., “Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease,” Annals of Neurology, vol. 35, no. 2, pp. 172–180, 1994. View at Google Scholar · View at Scopus
  12. C. R. Freed, P. E. Greene, R. E. Breeze et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. W. Olanow, C. G. Goetz, J. H. Kordower et al., “A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease,” Annals of Neurology, vol. 54, no. 3, pp. 403–414, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, “Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease,” Nature Medicine, vol. 14, no. 5, pp. 504–506, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Y. Li, E. Englund, J. L. Holton et al., “Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation,” Nature Medicine, vol. 14, no. 5, pp. 501–503, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. Y. Li, E. Englund, H. Widner et al., “Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease,” Movement Disorders, vol. 25, no. 8, pp. 1091–1096, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Yilong, C. Tang, T. Chaly et al., “Dopamine cell implantation in Parkinson's disease: long-term clinical and18F-FDOPA PET outcomes,” Journal of Nuclear Medicine, vol. 51, no. 1, pp. 7–15, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. P. Piccini, N. Pavese, P. Hagell et al., “Factors affecting the clinical outcome after neural transplantation in Parkinson's disease,” Brain, vol. 128, no. 12, pp. 2977–2986, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. Winkler, D. Kirik, and A. Björklund, “Cell transplantation in Parkinson's disease: how can we make it work?” Trends in Neurosciences, vol. 28, no. 2, pp. 86–92, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. P. Brundin, O. Pogarell, P. Hagell et al., “Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease,” Brain, vol. 123, no. 7, pp. 1380–1390, 2000. View at Google Scholar · View at Scopus
  21. M. Politis, K. Wu, C. Loane et al., “Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants,” Science Translational Medicine, vol. 2, no. 38, Article ID 38ra46, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. W. J. Freed, M. Poltorak, and J. B. Becker, “Intracerebral adrenal medulla grafts: a review,” Experimental Neurology, vol. 110, no. 2, pp. 139–166, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. C. G. Goetz, C. W. Olanow, W. C. Koller et al., “Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease,” New England Journal of Medicine, vol. 320, no. 6, pp. 337–341, 1989. View at Google Scholar · View at Scopus
  24. J. M. Schumacher, S. A. Ellias, E. P. Palmer et al., “Transplantation of embryonic porcine mesencephalic tissue in patients with PD,” Neurology, vol. 54, no. 5, pp. 1042–1050, 2000. View at Google Scholar · View at Scopus
  25. O. Lindvall, Z. Kokaia, and A. Martinez-Serrano, “Stem cell therapy for human neurodegenerative disorders - How to make it work,” Nature Medicine, vol. 10, supplement, pp. S42–S50, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. H. Kim, J. M. Auerbach, J. A. Rodríguez-Gómez et al., “Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease,” Nature, vol. 418, no. 6893, pp. 50–56, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. L. M. Björklund, R. Sánchez-Pernaute, S. Chung et al., “Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 4, pp. 2344–2349, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. F. E. O'Keeffe, S. A. Scott, P. Tyers et al., “Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease,” Brain, vol. 131, no. 3, pp. 630–641, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. L. Weiss, S. Medicetty, A. R. Bledsoe et al., “Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease,” Stem Cells, vol. 24, no. 3, pp. 781–792, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. G. Bouchez, L. Sensebé, P. Vourc'h et al., “Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease,” Neurochemistry International, vol. 52, no. 7, pp. 1332–1342, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Wernig, J. P. Zhao, J. Pruszak et al., “Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5856–5861, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. T. Vierbuchen, A. Ostermeier, Z. P. Pang, Y. Kokubu, T. C. Südhof, and M. Wernig, “Direct conversion of fibroblasts to functional neurons by defined factors,” Nature, vol. 463, no. 7284, pp. 1035–1041, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. D. E. Redmond, K. B. Bjugstad, Y. D. Teng et al., “Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12175–12180, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. L. Berry and T. Foltynie, “Gene therapy: a viable therapeutic strategy for Parkinson's disease?” Journal of Neurology, vol. 258, no. 2, pp. 179–188, 2011. View at Publisher · View at Google Scholar · View at PubMed
  35. W. M. Caudle, R. E. Colebrooke, P. C. Emson, and G. W. Miller, “Altered vesicular dopamine storage in Parkinson's disease: a premature demise,” Trends in Neurosciences, vol. 31, no. 6, pp. 303–308, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. L. Chen, Y. Ding, B. Cagniard et al., “Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice,” Journal of Neuroscience, vol. 28, no. 2, pp. 425–433, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. A. Björklund, T. Björklund, and D. Kirik, “Gene therapy for dopamine replacement in Parkinson's disease,” Science translational medicine, vol. 1, no. 2, pp. 2–ps2, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. M. Azzouz, E. Martin-Rendon, R. D. Barber et al., “Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease,” Journal of Neuroscience, vol. 22, no. 23, pp. 10302–10312, 2002. View at Google Scholar · View at Scopus
  39. Y. Shen, S. I. Muramatsu, K. Ikeguchi et al., “Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease,” Human Gene Therapy, vol. 11, no. 11, pp. 1509–1519, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. D. Kirik, B. Georgievska, C. Burger et al., “Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4708–4713, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. K. S. Bankiewicz, J. Forsayeth, J. L. Eberling et al., “Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC,” Molecular Therapy, vol. 14, no. 4, pp. 564–570, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. B. Jarraya, S. Boulet, G. S. Ralph et al., “Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia,” Science Translational Medicine, vol. 1, no. 2, p. 2ra4, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. L. Eberling, W. J. Jagust, C. W. Christine et al., “Results from a phase I safety trial of hAADC gene therapy for Parkinson disease,” Neurology, vol. 70, no. 21, pp. 1980–1983, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. C. W. Christine, P. A. Starr, P. S. Larson et al., “Safety and tolerability of putaminal AADC gene therapy for Parkinson disease,” Neurology, vol. 73, no. 20, pp. 1662–1669, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. E. Emborg, M. Carbon, J. E. Holden et al., “Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 3, pp. 501–509, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. P. A. LeWitt, A. R. Rezai, M. A. Leehey et al., “AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial,” The Lancet Neurology, vol. 10, no. 4, pp. 309–319, 2011. View at Publisher · View at Google Scholar
  47. L. F. H. Lin, D. H. Doherty, J. D. Lile, S. Bektesh, and F. Collins, “GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons,” Science, vol. 260, no. 5111, pp. 1130–1132, 1993. View at Google Scholar · View at Scopus
  48. I. Stromberg, L. Bjorklund, M. Johansson et al., “Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo,” Experimental Neurology, vol. 124, no. 2, pp. 401–412, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. D. M. Gash, Z. Zhang, A. Ovadia et al., “Functional recovery in parkinsonian monkeys treated with GDNF,” Nature, vol. 380, no. 6571, pp. 252–255, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. S. Gill, N. K. Patel, G. R. Hotton et al., “Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease,” Nature Medicine, vol. 9, no. 5, pp. 589–595, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. A. E. Lang, S. Gill, N. K. Patel et al., “Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease,” Annals of Neurology, vol. 59, no. 3, pp. 459–466, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. G. Nutt, K. J. Burchiel, C. L. Comella et al., “Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD,” Neurology, vol. 60, no. 1, pp. 69–73, 2003. View at Google Scholar · View at Scopus
  53. W. J. Marks, R. T. Bartus, J. Siffert et al., “Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial,” The Lancet Neurology, vol. 9, no. 12, pp. 1164–1172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Ceregene, “Ceregene announces clinical data from phase 2 clinical trial of cere-120 for Parkinson’s disease—longer term follow-up indicates modest efficacy in primary and related endpoints,” 2009, http://www.ceregene.com/press_052709.asp.
  55. D. Kirik, C. Winkler, and A. Björklund, “Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration,” Journal of Neuroscience, vol. 21, no. 8, pp. 2889–2896, 2001. View at Google Scholar · View at Scopus
  56. P. Hagell and M. A. Cenci, “Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective,” Brain Research Bulletin, vol. 68, no. 1-2, pp. 4–15, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. K. Marek and J. Seibyl, “Beta-cit scans without evidemce of dopaminergic deficit (SWEDD) in the elldopa-cit and calm-cit study: long-term imaging assessment,” Neurology, vol. 60, p. A293, 2003. View at Google Scholar
  58. C. Scherfler, J. Schwarz, A. Antonini et al., “Role of DAT-SPECT in the diagnostic work up of Parkinsonism,” Movement Disorders, vol. 22, no. 9, pp. 1229–1238, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. G. L. Defer, H. Widner, R. M. Marié, P. Rémy, and M. Levivier, “Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD),” Movement Disorders, vol. 14, no. 4, pp. 572–584, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. C. G. Goetz, S. Fahn, P. Martinez-Martin et al., “Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan,” Movement Disorders, vol. 22, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. J. G. Nutt, J. H. Carter, and W. R. Woodward, “Long-duration response to levodopa,” Neurology, vol. 45, no. 8, pp. 1613–1616, 1995. View at Google Scholar · View at Scopus
  62. S. I. Muramatsu, K. I. Fujimoto, S. Kato et al., “A phase i study of aromatic l-amino acid decarboxylase gene therapy for parkinson's disease,” Molecular Therapy, vol. 18, no. 9, pp. 1731–1735, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. R. A. Hauser, F. Deckers, and P. Lehert, “Parkinson's disease home diary: further validation amd implications for clinical trials,” Movement Disorders, vol. 19, no. 12, pp. 1409–1413, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. K. E. Lyons and R. Pahwa, “Electronic motor function diary for patients with Parkinson's disease: a feasibility study,” Parkinsonism and Related Disorders, vol. 13, no. 5, pp. 304–307, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. C. Colosimo, P. Martínez-Martín, G. Fabbrini et al., “Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations,” Movement Disorders, vol. 25, no. 9, pp. 1131–1142, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. J. R. Evans, S. L. Mason, C. H. Williams-Gray et al., “The natural history of treated Parkinson's disease in an incident, community based cohort,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 10, pp. 1112–1118, 2011. View at Publisher · View at Google Scholar · View at PubMed
  67. B. L. Den Oudsten, G. L. Van Heck, and J. De Vries, “The suitability of patient-based measures in the field of Parkinson's disease: a systematic review,” Movement Disorders, vol. 22, no. 10, pp. 1390–1401, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. Williams, S. Gill, T. Varma et al., “Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial,” The Lancet Neurology, vol. 9, no. 6, pp. 581–591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. D. J. Brooks, “Neuroimaging in Parkinson's disease,” NeuroRx, vol. 1, no. 2, pp. 243–254, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. P. K. Morrish, G. V. Sawle, and D. J. Brooks, “An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease,” Brain, vol. 119, no. 2, pp. 585–591, 1996. View at Google Scholar · View at Scopus
  71. P. Remy, Y. Samson, P. Hantraye et al., “Clinical correlates of [18F]fluorodopa uptake in five grafted Parkinsonian patients,” Annals of Neurology, vol. 38, no. 4, pp. 580–588, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. J. H. Kordower, T. B. Freeman, E. Y. Chen et al., “Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease,” Movement Disorders, vol. 13, no. 3, pp. 383–393, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. H. Kordower, T. B. Freeman, B. J. Snow et al., “Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease,” New England Journal of Medicine, vol. 332, no. 17, pp. 1118–1124, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. V. Cochen, M. J. Ribeiro, J. P. Nguyen et al., “Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue,” Movement Disorders, vol. 18, no. 8, pp. 928–932, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. P. Hagell and M. A. Cenci, “Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective,” Brain Research Bulletin, vol. 68, no. 1-2, pp. 4–15, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. P. Hagell, P. Piccini, A. Björklund et al., “Dyskinesias following neural transplantation in Parkinson's disease,” Nature Neuroscience, vol. 5, no. 7, pp. 627–628, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. M. Politis, W. H. Oertel, K. Wu et al., “Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio,” Movement Disorders, vol. 26, no. 11, pp. 1997–2003, 2011. View at Publisher · View at Google Scholar · View at PubMed
  78. M. Politis, K. Wu, C. Loane et al., “Staging of serotonergic dysfunction in Parkinson's Disease: an in vivo 11C-DASB PET study,” Neurobiology of Disease, vol. 40, no. 1, pp. 216–221, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. S. C. Chow, J. Shao, and H. Wang, Sample Size Calculation in Clinical Research, Chapman & Hall/CRC, New York, NY, USA, 2nd edition, 2008.
  80. R. L. Albin, “Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls,” Journal of Medical Ethics, vol. 28, no. 5, pp. 322–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Shetty, J. H. Friedman, K. Kieburtz, F. J. Marshall, and D. Oakes, “The placebo response in Parkinson's disease,” Clinical Neuropharmacology, vol. 22, no. 4, pp. 207–212, 1999. View at Google Scholar
  82. C. G. Goetz, J. Wuu, M. P. McDermott et al., “Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions,” Movement Disorders, vol. 23, no. 5, pp. 690–699, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. D. W. Dickson, H. Fujishiro, C. Orr et al., “Neuropathology of non-motor features of Parkinson disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, supplement 3, pp. S1–S5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Gögel, M. Gubernator, and S. L. Minger, “Progress and prospects: stem cells and neurological diseases,” Gene Therapy, vol. 18, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at PubMed